Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Average Rating of “Hold” from Analysts

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has received an average recommendation of “Hold” from the six research firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $3.2250.

LXRX has been the topic of several research reports. Wall Street Zen downgraded Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a research report on Thursday.

Institutional Trading of Lexicon Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Savant Capital LLC grew its holdings in shares of Lexicon Pharmaceuticals by 33.2% in the 2nd quarter. Savant Capital LLC now owns 69,578 shares of the biopharmaceutical company’s stock valued at $66,000 after buying an additional 17,348 shares during the period. Bank of America Corp DE lifted its holdings in Lexicon Pharmaceuticals by 80.1% during the third quarter. Bank of America Corp DE now owns 57,804 shares of the biopharmaceutical company’s stock worth $78,000 after acquiring an additional 25,707 shares in the last quarter. Vermillion & White Wealth Management Group LLC grew its stake in Lexicon Pharmaceuticals by 400.0% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 32,500 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 26,000 shares during the period. Hudson Bay Capital Management LP bought a new stake in shares of Lexicon Pharmaceuticals in the second quarter worth about $26,000. Finally, Vanguard Personalized Indexing Management LLC raised its position in shares of Lexicon Pharmaceuticals by 77.8% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 65,330 shares of the biopharmaceutical company’s stock worth $62,000 after purchasing an additional 28,594 shares during the period. 74.70% of the stock is owned by institutional investors.

Lexicon Pharmaceuticals Trading Down 3.4%

LXRX opened at $1.70 on Monday. Lexicon Pharmaceuticals has a 1-year low of $0.28 and a 1-year high of $1.83. The stock has a market capitalization of $617.78 million, a PE ratio of -8.95 and a beta of 0.71. The company has a current ratio of 5.64, a quick ratio of 5.63 and a debt-to-equity ratio of 0.47. The firm has a 50-day moving average price of $1.31 and a two-hundred day moving average price of $1.27.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings results on Thursday, November 6th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.03. The business had revenue of $14.18 million for the quarter, compared to analysts’ expectations of $5.81 million. Lexicon Pharmaceuticals had a negative net margin of 96.77% and a negative return on equity of 52.90%. As a group, equities analysts anticipate that Lexicon Pharmaceuticals will post -0.66 earnings per share for the current fiscal year.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.